DaShenLin Pharmaceutical Group Co., Ltd.

SHSE:603233 Stok Raporu

Piyasa değeri: CN¥18.2b

DaShenLin Pharmaceutical Group Yönetim

Yönetim kriter kontrolleri 1/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Guoqiang Ke

İcra Kurulu Başkanı

CN¥2.3m

Toplam tazminat

CEO maaş yüzdesin/a
CEO görev süresi5.8yrs
CEO sahipliği0.02%
Yönetim ortalama görev süresiVeri yok
Yönetim Kurulu ortalama görev süresi1.8yrs

Son yönetim güncellemeleri

Recent updates

Take Care Before Diving Into The Deep End On DaShenLin Pharmaceutical Group Co., Ltd. (SHSE:603233)

Sep 30
Take Care Before Diving Into The Deep End On DaShenLin Pharmaceutical Group Co., Ltd. (SHSE:603233)

DaShenLin Pharmaceutical Group Co., Ltd. Just Missed Earnings - But Analysts Have Updated Their Models

Sep 03
DaShenLin Pharmaceutical Group Co., Ltd. Just Missed Earnings - But Analysts Have Updated Their Models

DaShenLin Pharmaceutical Group (SHSE:603233) May Have Issues Allocating Its Capital

Aug 20
DaShenLin Pharmaceutical Group (SHSE:603233) May Have Issues Allocating Its Capital

Not Many Are Piling Into DaShenLin Pharmaceutical Group Co., Ltd. (SHSE:603233) Stock Yet As It Plummets 27%

Jun 17
Not Many Are Piling Into DaShenLin Pharmaceutical Group Co., Ltd. (SHSE:603233) Stock Yet As It Plummets 27%

Does DaShenLin Pharmaceutical Group (SHSE:603233) Have A Healthy Balance Sheet?

Jun 09
Does DaShenLin Pharmaceutical Group (SHSE:603233) Have A Healthy Balance Sheet?

Are Investors Undervaluing DaShenLin Pharmaceutical Group Co., Ltd. (SHSE:603233) By 30%?

May 21
Are Investors Undervaluing DaShenLin Pharmaceutical Group Co., Ltd. (SHSE:603233) By 30%?

Some May Be Optimistic About DaShenLin Pharmaceutical Group's (SHSE:603233) Earnings

May 06
Some May Be Optimistic About DaShenLin Pharmaceutical Group's (SHSE:603233) Earnings

Investors Could Be Concerned With DaShenLin Pharmaceutical Group's (SHSE:603233) Returns On Capital

Apr 09
Investors Could Be Concerned With DaShenLin Pharmaceutical Group's (SHSE:603233) Returns On Capital

Lacklustre Performance Is Driving DaShenLin Pharmaceutical Group Co., Ltd.'s (SHSE:603233) Low P/E

Mar 17
Lacklustre Performance Is Driving DaShenLin Pharmaceutical Group Co., Ltd.'s (SHSE:603233) Low P/E

CEO

Guoqiang Ke (42 yo)

5.8yrs

Görev süresi

CN¥2,308,800

Tazminat

Mr. Guoqiang Ke is General Manager of DaShenLin Pharmaceutical Group Co., Ltd. from February 28, 2019 and serves as DIrector since February 03, 2023. He was Deputy General Manager of DaShenLin Pharmaceutic...


Yönetim Kurulu Üyeleri

İsimPozisyonGörev süresiTazminatSahiplik
Guoqiang Ke
GM & Director1.8yrsCN¥2.31m0.025%
CN¥ 4.5m
Qun Fei Tan
Deputy GM & Director1.8yrsCN¥2.05m0.024%
CN¥ 4.3m
Zhi Hui Chen
Chairman of Supervisory Board & Deputy Director of Human Resources Department - Guangdong Provinceno dataVeri yok0.012%
CN¥ 2.1m
Yun Feng Ke
Chairman of the Boardno dataCN¥2.49m21.3%
CN¥ 3.9b
Guo Liu
Independent Directorno dataCN¥73.40kVeri yok
Zu Yao Su
Independent Directorno dataCN¥80.00kVeri yok
Jie Li
Directorno dataVeri yokVeri yok
Li Ping Lu
Independent Directorno dataCN¥80.00kVeri yok
Jinshu Shi
Staff Supervisorno dataVeri yok0.00055%
CN¥ 99.8k
Wensheng Chen
Supervisor1.8yrsVeri yokVeri yok

1.8yrs

Ortalama Görev Süresi

54yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 603233 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilmiyor ( 1.8 yıllık ortalama görev süresi), bu da yeni bir yönetim kurulu olduğunu gösteriyor.